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Abstract
The present review assesses the data on long-term outcome after coronary stenting.
Histological, angiographical and intravascular imaging data have shown that the insertion of
stents constitutes only a transient stimulus to lumen renarrowing, that this process is almost
complete at 6 months and that a certain degree of neointima regression is also possible
after this time. Clinical data have confirmed the sustained benefit of stenting in the long term.
Careful selection of optimal stent designs and application of the recent advances in
adjunctive pharmacological therapy are currently effective strategies to improve both short-
and long-term results with coronary stenting. However, further efforts are needed and are
ongoing to combat restenosis, a process that counters the excellent short-term results of
stenting in the long term.
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Introduction
Since the introduction of percutaneous transluminal coro-
nary angioplasty (PTCA), the first use of coronary stenting
in clinical practice in 1986 [1••] was the major break-
through in the treatment of patients with coronary artery
disease. Coronary stenting was introduced to combat two
limitations of conventional PTCA: acute vessel closure and
late lumen renarrowing. Now, after 15 years of continuous
refinement, stenting has become the dominant percuta-
neous coronary intervention. Over these years, stent
designs, stent delivery systems, stent deployment tech-
niques and adjunctive antithrombotic therapy have all
changed dramatically [2].
The earliest concern with the use of stenting was its
thrombogenicity and potential for disastrous early severe
thrombotic complications [3]. Potent anticoagulation
therapy with prolonged heparin administration followed
by coumarin derivatives only amplified the risk of bleed-
ing complications, without resolving the problem of stent
thrombosis [4]. Considerable efforts were then focused
on understanding the principal mechanisms of stent
thrombosis [5], on technical refinements aimed at
improving the immediate lumen gain through high-pres-
sure inflation under the guidance of intravascular ultra-
sound [6], and on the search for more effective
antithrombotic therapies [7].http://cvm.controlled-trials.com/content/1/1/048
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The ISAR (Intracoronary Stenting and Antithrombotic
Regimen) trial in 1996 [8••] and the other trials that fol-
lowed in 1998 [9,10••] definitively established the role of
the combined antiplatelet therapy (ticlopidine plus aspirin)
in minimizing the risk of stent thrombosis. The favourable
results achieved more recently with newer antiplatelet
agents such as glycoprotein IIb/IIIa inhibitors [11••] further
strengthened the value of the pharmacological approach in
the prevention of thrombotic events after stenting. The
trials mentioned above were critical in defining stent place-
ment protocols and in guiding future efforts in this field; this
became even more apparent after the demonstrated failure
of high-pressure deployment to favourably impact on the
risk of thrombosis and restenosis after stenting [12•].
Several randomized trials have examined the value of coro-
nary stenting in various subsets of lesions and patients. For
selected lesions situated in native coronary vessels with a
diameter of 3 mm or more, the BENESTENT (Belgium-
Netherland Stent) [13••] and STRESS (Stent Restenosis
Study) [14••] trials demonstrated a significant reduction in
angiographic restenosis and need for target vessel revas-
cularization (TVR) achieved with stenting compared with
PTCA. Stenting also proved superior to PTCA for lesions in
coronary bypass grafts, as shown by the significant reduc-
tion in incidence of adverse clinical events at 8 months and
the trend toward a lower rate of angiographic restenosis
[15•]. However, these advantages of stenting could not be
reproduced for lesions in smaller native vessels [16].
When compared with primary PTCA, primary stenting in
acute myocardial infarction (AMI) was associated with
decreased restenosis and need for TVR, but without any
benefit in hard end-points such as death or reinfarction
[17]. In contrast, optimizing the adjunctive antithrombotic
therapy with the addition of glycoprotein IIb/IIIa blockade
(abciximab) enabled greater myocardial salvage and better
clinical outcome with stenting than with thrombolysis in
patients with AMI [18]. However, the present review does
not discuss the results of primary stenting in AMI due to
the paucity of long-term data.
There is no doubt about the excellent acute and good mid-
term results achieved with stenting. This is the reason why
this treatment option is used so frequently, even for indica-
tions that have not been proven by properly designed ran-
domized trials. However, there are doubts regarding the
long-term advantages of this intervention. The introduction
of a new treatment strategy often raises the question of
long-term results. This question is even more important in
the case of stenting. Stenting consists of the permanent
implantation of a foreign body, with the potential of adverse
effects in the long term through the lasting interaction with
the vessel wall and the chronic strain imposed on that
structure. On the other extreme of concerns regarding this
treatment, stents might collapse with time, thereby abrogat-
ing the initial benefit. The 15 years of experience with this
treatment and the plethora of data from histopathological,
angiographical, intravascular imaging and clinical studies
have enabled a more realistic perspective about the long-
term efficacy of coronary stenting.
Histopathologic data
The pathobiological responses of the vessel wall to stent
insertion have been characterized by numerous animal
studies and fewer human investigations that used stented
vessels obtained at autopsy, stented vein grafts excised at
surgery and vessel wall tissue specimens retrieved with
atherectomy. The response of the vessel wall to stenting is
qualitatively characterized by the typical features of a
response to injury. Stent-induced injury triggers a
sequence of events that may be categorized as thrombo-
sis, inflammation and proliferation [19•]. Stents provoke a
higher degree of injury than does balloon dilatation alone,
and this is followed by mural deposition of platelet-rich
thrombi, which occurs within the first few days [20] and is
demonstrable until 30 days after the intervention [21].
Another important response to stent-induced injury is the
inflammatory reaction, as demonstrated by the accumula-
tion at the injury site of acute inflammatory cells (neu-
trophils) during the first 30 days and chronic inflammatory
cells (lymphocytes and macrophages) thereafter [20]. The
degree of the inflammatory reaction correlates with the
degree of injury, and both thrombosis and inflammation
are also dependent on the stent design used [22•].
The higher degree of injury, thrombosis and inflammation
observed after stenting is associated with more extensive
neointima formation than after plain PTCA [23]. Restenotic
tissue from patients after stenting is richer in smooth
muscle cells and is poorer in collagen than restenotic
tissue from patients after PTCA [24]. Also, neointima pre-
sents more apoptosis after stenting than after PTCA [25].
Both inhibition of smooth muscle cell proliferation and/or
enhancement of apoptosis are logical targets of strategies
for prevention of restenosis. Finally, remodelling, which is
the principal mechanism of restenosis after PTCA, plays
almost no role at all in in-stent restenosis [19•].
Although the differences in the magnitude of the compo-
nents of restenosis between stenting and PTCA have been
well described, an accurate characterization of the time
course of the restenotic processes that occur after these
interventions is still lacking. The data available from sepa-
rate pathological studies suggest that the healing process
after stenting does not take much longer than that after
PTCA. Full re-endothelialization and stability of the neoin-
tima overlying the stent seem to be achieved by 12 weeks
after stenting, on the basis of autopsy studies in humans
[26]. Therefore, the histopathological data do not provide
reasons to believe that the documented advantages of
stenting over PTCA will be eliminated in the long run.Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Kastrati et al
Angiographic and intravascular imaging data
Although stenting reduces the incidence of angiographic
restenosis by 25–30% in comparison with PTCA
[13••,14••], restenosis remains the major drawback for this
intervention also. Restenosis mostly affects particular
subsets of patients [27], and baseline conventional clini-
cal, lesion-related and procedure-related variables may
only partly explain the risk for this complication [28]. A sig-
nificant part of this risk appears to be related to known or
as yet unknown genetic factors [29].
Intravascular ultrasound investigations [30] have confirmed
neointima formation and remodelling as the major contribu-
tors to restenosis after stenting and PTCA, respectively.
The temporal pattern of luminal changes appears to be
similar within the first 6 months after stenting and PTCA
[31]. Most of the lumen renarrowing takes place within the
first 3 months after stenting, with virtually no change occur-
ring between 6 and 12 months; the incidence of restenosis
was 22% after 3 months, 32% after 6 months, and
remained essentially constant at 33% by 1 year [32•]. More
importantly, the minimal lumen at the stented site initially
was surprisingly enlarged during the interval between 1
and 3 years after the procedure [33•]. In fact, serial
angioscopy in patients after stenting has shown that thin-
ning of neointima occurs after 6 months [34]. The mecha-
nism that may lead to altered expression of genes that
interfere with apoptosis in the neointima tissue remains to
be investigated. If confirmed, these findings may also have
important implications regarding how asymptomatic
patients with in-stent restenosis should be managed.
Routine angiographic follow up is believed by some to
increase the risk of ‘oculostenotic reflex’, which increases
the number of reinterventions. The number of reinterven-
tions was twice as high among stent patients who were
subrandomized to angiographic restudy than among those
assigned only clinical follow up in the BENESTENT II trial
[35]. On the other hand, PTCA patients with systematic
angiographic follow up at 6 months had a higher rate of
reinterventions, but a lower mortality at 10 years after the
procedure than did their counterparts without angio-
graphic restudy at 6 months [36].
Clinical data
Table 1 shows the clinical results at 1 year that were
reported by the major randomized trials that compared
stenting with conventional PTCA or coronary artery bypass
grafting (CABG). Where data are available, the incidence
of angiographic restenosis at 6 months is also shown. The
BENESTENT [13••,37], BENESTENT II [35] and STRESS
[14••,38] trials included selected subsets of patients and
lesions. The ARTS (Arterial Revascularization Therapy
Study) [39] enrolled patients with multivessel interventions.
The device used was the Palmaz–Schatz stent (Cordis, a
Johnson & Johnson Company, Warren, NJ, USA) in the
BENESTENT, STRESS and EPISTENT (Evaluation of
Platelet IIb/IIIa Inhibitor for Stenting) [11••] trials, the
heparin-coated Palmaz–Schatz stent in the BENESTENT II
trial, and Crown (Cordis) or CrossFlex (Cordis) stent in the
ARTS trial. As adjunctive pharmacological therapy to
stenting, full anticoagulation was used in the BENSTENT
and STRESS trials, and aspirin plus ticlopidine in the
Table 1
Clinical results at 1 year in major randomized trials with coronary stenting
Angiographic restenosis
Study/Procedure n rate (%) Death (%) MI (%) CABG (%) PTCA (%) MACE (%)
BENESTENT [13••,17]
Stent 259 22* 1.2 3.5 6.9 10.0* 23.2*
PTCA 257 32 0.8 1.9 5.1 20.6 31.5
STRESS [14••,38]
Stent 205 32* 1.5 3.4 5.8 15.1 21.0
PTCA 202 42 2.0 3.5 8.9 16.4 26.2
BENESTENT II [35]
Stent (heparin coated) 413 16* 1.0 1.9 1.9 9.4* 15.7*
PTCA 410 31 1.0 1.5 1.5 15.6 22.4
EPISTENT [11••]
Stent + abciximab 794 31† 1.0 4.4 5.8 13.6* 18.6*
PTCA + abciximab 796 40 2.1 6.4 6.3 18.3 24.9
ARTS [39]
Stent 600 N/A 2.5 5.3 4.7* 12.2* 26.3*
CABG 605 N/A 2.8 4.0 0.5 3.0 12.2
Study acronyms are defined in the text. *P < 0.05 for the comparison between stent and respective control arm (PTCA or CABG). †Restenosis
data presented at the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, LA, USA, 1999. MACE, any major
adverse clinical event; MI, myocardial infarction (defined as either Q-wave infarction or creatine kinase elevation ³5 times the upper normal limit);
N/A, not available.BENESTENT II, EPISTENT and ARTS trials. In addition,
glycoprotein IIb/IIIa inhibition with abciximab was given
periprocedurally in the EPISTENT trial.
As shown in Table 1, stenting is associated with a relative
reduction of 20–30% in the cumulative 1-year incidence
of adverse clinical events when compared with PTCA.
This is exclusively the result of the reduced need for rein-
terventions. On the other hand, the ARTS trial showed
that multivessel stenting may achieve similar clinical
results at 1 year to those of CABG in terms of hard end-
points, such as mortality and myocardial infarction, at the
cost of more frequent need for reinterventions, mostly per-
cutaneous coronary interventions. However, when the
ARTS results are interpreted in the context of the previous
trials that compared PTCA with CABG, multivessel stent-
ing seems to reduce the difference in the incidence of
adverse clinical events between the surgical and the per-
cutaneous approaches.
In addition to the experimental evidence, there are now
sufficient clinical data to support the independent role of
stent type in the long-term results achieved with stenting.
In a randomized comparison of five stent types [40],
1-year event-free survival varied from 69.4 to 78.9%
(P<0.02) depending on the stent design used. These
findings show the potential of stent technologies to
improve the long-term outcome of patients treated with
this technique.
For several years, the use of stents remained limited and
mostly confined to bail-out situations or coronary bypass
grafts. Following reports of advantages of stenting over
PTCA and the radical improvement in antithrombotic
therapy, there has been a great increase in the use of
stents during the past 5 years. This explains why studies
with follow-up periods longer than 1 year usually include a
limited number of patients. Several factors should be con-
sidered that can have a profound influence on the long-
term clinical findings. The results with coronary stenting
are dependent on the characteristics of patients included
[29], on the antithrombotic regimen used as an adjunct to
stenting [8••,10••,11••], and on the particular stent design
implanted [40,41]. Long-term outcome after stenting also
reflects the progression of coronary atherosclerosis, pre-
vention of which should represent the primary focus of the
management of these patients.
A summary of the long-term results reported by studies
with a follow-up period of at least 24 months is presented
in Table 2. The risk profile of the patients included in these
studies is considerably different, with only selected lesions
in native vessels for some studies [13••,14••,33•] and bail-
out situations in others [4,42]. The Palmaz–Schatz stent
was used in most of the studies [4,33•,43–46]. Eeckhout
et al [42] used the Wallstent (Boston Scientific Corp,
Natick, MA, USA) and van Domburg et al [47] use differ-
ent stents, including the Wallstent. Except for the study of
van Domburg et al [47], all of the other studies applied full
anticoagulation as the poststenting regimen.
Two studies reported on the long-term results of random-
ized comparisons between stent and PTCA. At 5 years,
BENESTENT investigators [46] reported a 34.5% rate of
adverse events after stenting, and a 40.2% rate after
PTCA, which represents a nonsignificant relative reduc-
tion of 14%. This was exclusively due to a significant
reduction of 37% in the need for repeat PTCA (17.3% in
the stent and 27.6% in the PTCA arm). Similar results
were reported by the other randomized trial, conducted by
Betriu et al [45]. The incidence of adverse events at 4
years decreased significantly from 29.9% after PTCA to
16.9% after stenting, mostly because of the reduction in
the rate of repeat PTCA from 22.3% to 10.7%.
http://cvm.controlled-trials.com/content/1/1/048
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Table 2
Clinical results at 24 months or more after coronary stenting
Follow up
Reference n (months)† Death (%) MI (%) TVR (%) MACE (%)
[42] 123 42 13 22 21 49
[4] 301 24 4.6 4.3* 20.4 29.3
[43] 65 39 10.8 6.2 30.8 44.0
[44] 175 54 13.7 12.6 39.4 49.7
[33•] 143 36 9.1 5.6* 20.4 25.4
[45] 229 48 2.7 2.2* 12.0 16.9
[46] 259 60 5.9 7.8 25.0 34.5
[47] 1000 29 8.2 12.8 30.3 45.0
*Nonfatal infarctions. †Mean or median follow-up period. MACE, major adverse clinical event; MI, myocardial infarction.Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Kastrati et al
In the retrospective study of van Domburg et al [47], a com-
parative analysis between the subgroup treated with antico-
agulation therapy and that treated with antiplatelet agents
was performed at 2 years after stenting. Interestingly, the
advantages of antiplatelet therapy in terms of reduced risk
of myocardial infarction and need for repeat interventions
were maintained over the entire follow-up period. The
concept that even short-term antithrombotic therapy is able
to achieve a long-term benefit is best illustrated by the
EPISTENT [11••] results: adding abciximab to the peripro-
cedural therapy was associated with a significant 57%
reduction in 1-year mortality (1.0% in stent plus abciximab
versus 2.3% in stent plus placebo). It is readily conceivable
that this is the result of the drastic reduction in the rate of
postprocedural myocardial infarction observed with abcix-
imab. These findings indicate another source of improve-
ment of long-term results after stenting, namely further
optimization of the adjunctive pharmacological therapy.
In-stent restenosis poses a major threat to long-term
outcome after stenting; it may be focal or diffuse [48]. Par-
ticularly when diffuse, in-stent restenosis is a real manage-
ment challenge for interventional cardiologists because of
its high recurrence rate. Various forms of percutaneous
coronary intervention, including plain PTCA, repeat stenting,
directional and rotational atherectomy, and excimer laser
angioplasty, have been used to treat in-stent restenosis.
Considering that lumen encroachment in the stented site is
the consequence of an exuberant neointimal tissue growth,
debulking techniques appear to be attractive strategies for
treating this complication. Contrary to expectations,
however, rotational atherectomy, followed by low-pressure
balloon dilatation proved to be inferior to plain PTCA in the
ARTIST (Angioplasty versus Rotation for the Treatment of
In-Stent Stenosis/Occlusion) randomized trial [49].
The experience to date indicates that several strategies
designed to prevent restenosis have yielded disappointing
results, but brachytherapy may have promise. In a small
series of 55 patients with a particularly high risk for
restenosis who were randomly assigned to either intra-
coronary g-radiation or placebo therapy during the inter-
vention [50], there was a significant reduction in the need
for reintervention at 3 years, from 48.3 to 15.4%. Encour-
aging results in reducing the recurrence of in-stent
restenosis were also reported with the use of intracoro-
nary b-radiation [51]. Intensive work is being done in this
field and results from large clinical trials are still pending.
Conclusion
Coronary stenting is increasingly being used because of
the excellent short-term results, the ability to prevent
abrupt vessel closure that may occur after plain PTCA,
and the reduced risk of restenosis that has been demon-
strated for a number of indications. Histologic, angio-
graphic and intravascular imaging data have evidenced
the different mechanisms of restenosis between stenting
and PTCA. They have also shown that the insertion of
stents constitutes only a transient stimulus to lumen renar-
rowing, that this process is almost complete at 6 months,
and that a certain degree of neointima regression is also
possible after this time. Clinical data have confirmed the
sustained benefit of stenting in the long term. Careful
selection of optimal stent designs and application of the
recent advances in adjunctive pharmacological therapy
are currently effective strategies to improve both short-
term and long-term results with coronary stenting.
However, further efforts are needed and are on-going to
combat restenosis, a process that counters the excellent
short-term results of stenting in the long term.
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